RSS Feeds
Search

Companies

Companies

Displaying 1..7 of 7 - per page
Order by
Astex Therapeutics Limited
Astex uses a fragment-based approach to discover and develop small molecule molecularly targeted drugs for the treatment of cancer and other human diseases with significant unmet medical need. More
Ardana Bioscience
Ardana Bioscience is a speciality pharmaceutical company which aims to discover, develop and market innovative products which promote better reproductive health and address the considerable unmet need More
Astellas Pharma Europe (formerly Yamanouchi and Fujisawa Europe)
Prescription pharmaceutical products More
Speciality European Pharma
Speciality European Pharma was founded in 2006 to acquire, develop, register and commercialise speciality therapeutic products for the expanding European market. More
BioInteractions Limited UK
BioInteractions Ltd is a natural first in solving biocompatible problems to the medical device world. We deliver practical and economical solutions, tailored to the demands of medical device companies More
Amersham
A world leader in the provision of products and services for in vivo medical diagnosis and in life sciences More
Pro-Cure Therapeutics Ltd
More
Displaying 1..7 of 7 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Prostate Cancer Drug Discoveries: What the Future Holds
Nov 2009 - 160 pages - $2,265
Jevtana (Cabazitaxel) - Positive Recommendation in the EU for Metastatic Castration-Resistant Prostate Cancer
Mar 2011 - 5 pages - $500
Epidemiology: Prostate Cancer – Incidence and prevalence reaches new heights due to testing, risk factors, and an aging population
Mar 2011 - 34 pages - $5,700
FDA Approves Zytiga (Abiraterone Acetate) for the Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer
May 2011 - 5 pages - $500
Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer
May 2011 - 5 pages - $500
Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology
Mar 2011 - 120 pages - $3,500
Company Financials: Cougar Biotechnology, Inc.
Jan 2010 - $75
Prostate Cancer Therapy Area Pipeline Report
Nov 2010 - 1011 pages - $1,495
US Oncology, Inc. - SWOT Analysis
Nov 2010 - 26 pages - $125
Prostate Cancer - Pipeline Assessment and Market Forecasts to 2020
Dec 2010 - 203 pages - $3,500
More Related Market Research Reports >>>

Your selection

Therapeutic target
Oncology del
Prostate cancer del
Geographic location
Europe del
United Kingdom del

Browse By

Industry sector
Academic/Research
Animal health
Biotechnology
Diagnostic
Drug delivery
Drug discovery
Medical device
Non-profit org./Government
Pharmaceutical
Research tools
Service
Therapeutic target
Adenocarcinoma
Benign prostatic hypertrophy

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us